Aller au contenu

Publications scientifiques

  • article Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É and Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM

    Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases t…

    Can Urol Assoc J 2026.

    DOI PUBMED
  • article Zamanian A, Rousseau É and Buteau FA, Arsenault F, Beaulieu A, April G, Juneau D, Plouznikoff N, Turcotte ÉE, Allard C, Richard PO, Saad F, Guérin B, Pouliot F, Beauregard JM

    The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study

    Cancer Imaging 25 (1), 2025.

    DOI PUBMED
  • article Akhavanallaf A, Lu Z, Peterson AB, Blakkisrud J, Kurkowska S, Yadav S, Wang C, Uribe C, Stokke C, Rahmim A, Wong KK, Beauregard JM, Hope TA, Sjögreen Gleisner K, Dewaraja YK

    Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data

    J Nucl Med 66 (7), 2025.

    DOI PUBMED
  • article Mansouri Z, Salimi Y, Akhavanallaf A, Shiri I, Teixeira EPA, Hou X, Beauregard JM, Rahmim A, Zaidi H

    Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy

    Eur J Nucl Med Mol Imaging 51 (6), 2024.

    DOI PUBMED
  • article Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, Sartor O, Tutrone RF, Oz OK, Courtney KD, Delpassand ES, Nordquist LT, Osman MM, Chi KN, Sparks R, George N, Hawley SM, Wu W, Jensen JD, Fleshner NE

    Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohor…

    Front Oncol 14 2024.

    DOI PUBMED
  • article Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, Lévesque É and Castonguay V, Marcoux N, Lodde M, Juneau D, Hamilou Z, Lattouf JB, Buteau FA, Pavic M, Castilloux JF, Neveu B, Bouvet GF, Allard C, Tétu A, Guérin B, Beauregard JM and

    Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

    J Nucl Med 65 (11), 2024.

    DOI PUBMED
  • article Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M

    Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours

    Eur J Nucl Med Mol Imaging 51 (8), 2024.

    DOI PUBMED
  • article Laverdière I, Matte G, Darveau M, Beauregard JM

    Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of Nuclear Medicine Patients for Comprehensive Pharmaceutical Care

    J Nucl Med 65 (8), 2024.

    DOI PUBMED
  • article Wild D, Grønbæk H, Navalkissoor S, Haug A, Nicolas GP, Pais B, Ansquer C, Beauregard JM, McEwan A, Lassmann M, Pennestri D, Volteau M, Lenzo NP, Hicks RJ

    A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

    Eur J Nucl Med Mol Imaging 51 (1), 2023.

    DOI PUBMED
  • article Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J

    Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate …

    Lancet Oncol 24 (6), 2023.

    DOI PUBMED
  • article Zahed H, Beauregard JM, Abikhzer G, Rush C, Probst S

    Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT

    Clin Nucl Med 48 (1), 2023.

    DOI PUBMED
  • article Beauregard JM, Rahmim A

    Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)

    Eur J Nucl Med Mol Imaging 49 (2), 2022.

    DOI PUBMED